Secreted frizzled related protein 3 in chronic heart failure: Analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA)

Erik Tandberg Askevold, Lars Gullestad, Ståle Nymo, John Kjekshus, Arne Yndestad, Roberto Latini, John G F Cleland, John J V McMurray, Pål Aukrust, Thor Ueland

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background We have previously demonstrated an association between increased sFRP3 expression and adverse outcome in a population of HF irrespective of cause and left ventricular ejection fraction. In this study we evaluated the prognostic value of sFRP3 in older patients with chronic systolic HF of ischemic origin. Methods We evaluated sFRP3, by tertiles, as a risk factor for the primary endpoint (cardiovascular [CV] mortality, nonfatal myocardial infarction, nonfatal stroke), all-cause mortality, CV mortality, death from worsening HF (WHF), any coronary event, including sudden death, as well as hospitalizations for CV causes and WHF in 1444 patients from the CORONA population, randomly assigned to 10 mg rosuvastatin or placebo. Results Kaplan-Meier curves for the primary endpoint, as well as all-cause- and CV mortality revealed a markedly better survival for patients with sFRP3 levels in the middle tertile of compared to the 1st and 3rd tertile. In multivariable Cox-regression, after full adjustment including high-sensitive CRP and NT-proBNP, a lower event rate for the primary end point, all cause and CV mortality was observed for patients with tertile 2 sFRP3 levels (HR 0.57 [0.44-0.74], 0.55 [0.44-0.74] and 0.52 [0.39-0.69]; p

Original languageEnglish
Article numbere0133970
JournalPLoS One
Volume10
Issue number8
DOIs
Publication statusPublished - Aug 19 2015

Fingerprint

heart failure
Failure analysis
Heart Failure
Mortality
endpoints
proteins
death
myocardial infarction
Sudden Death
stroke
Stroke Volume
Population
placebos
Hospitalization
risk factors
Stroke
Myocardial Infarction
Placebos
frizzled related protein-3
Rosuvastatin Calcium

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Secreted frizzled related protein 3 in chronic heart failure : Analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA). / Askevold, Erik Tandberg; Gullestad, Lars; Nymo, Ståle; Kjekshus, John; Yndestad, Arne; Latini, Roberto; Cleland, John G F; McMurray, John J V; Aukrust, Pål; Ueland, Thor.

In: PLoS One, Vol. 10, No. 8, e0133970, 19.08.2015.

Research output: Contribution to journalArticle

Askevold, ET, Gullestad, L, Nymo, S, Kjekshus, J, Yndestad, A, Latini, R, Cleland, JGF, McMurray, JJV, Aukrust, P & Ueland, T 2015, 'Secreted frizzled related protein 3 in chronic heart failure: Analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA)', PLoS One, vol. 10, no. 8, e0133970. https://doi.org/10.1371/journal.pone.0133970
Askevold, Erik Tandberg ; Gullestad, Lars ; Nymo, Ståle ; Kjekshus, John ; Yndestad, Arne ; Latini, Roberto ; Cleland, John G F ; McMurray, John J V ; Aukrust, Pål ; Ueland, Thor. / Secreted frizzled related protein 3 in chronic heart failure : Analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA). In: PLoS One. 2015 ; Vol. 10, No. 8.
@article{0e6aa127ad1c4d929e4823c9107523f9,
title = "Secreted frizzled related protein 3 in chronic heart failure: Analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA)",
abstract = "Background We have previously demonstrated an association between increased sFRP3 expression and adverse outcome in a population of HF irrespective of cause and left ventricular ejection fraction. In this study we evaluated the prognostic value of sFRP3 in older patients with chronic systolic HF of ischemic origin. Methods We evaluated sFRP3, by tertiles, as a risk factor for the primary endpoint (cardiovascular [CV] mortality, nonfatal myocardial infarction, nonfatal stroke), all-cause mortality, CV mortality, death from worsening HF (WHF), any coronary event, including sudden death, as well as hospitalizations for CV causes and WHF in 1444 patients from the CORONA population, randomly assigned to 10 mg rosuvastatin or placebo. Results Kaplan-Meier curves for the primary endpoint, as well as all-cause- and CV mortality revealed a markedly better survival for patients with sFRP3 levels in the middle tertile of compared to the 1st and 3rd tertile. In multivariable Cox-regression, after full adjustment including high-sensitive CRP and NT-proBNP, a lower event rate for the primary end point, all cause and CV mortality was observed for patients with tertile 2 sFRP3 levels (HR 0.57 [0.44-0.74], 0.55 [0.44-0.74] and 0.52 [0.39-0.69]; p",
author = "Askevold, {Erik Tandberg} and Lars Gullestad and St{\aa}le Nymo and John Kjekshus and Arne Yndestad and Roberto Latini and Cleland, {John G F} and McMurray, {John J V} and P{\aa}l Aukrust and Thor Ueland",
year = "2015",
month = "8",
day = "19",
doi = "10.1371/journal.pone.0133970",
language = "English",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

TY - JOUR

T1 - Secreted frizzled related protein 3 in chronic heart failure

T2 - Analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA)

AU - Askevold, Erik Tandberg

AU - Gullestad, Lars

AU - Nymo, Ståle

AU - Kjekshus, John

AU - Yndestad, Arne

AU - Latini, Roberto

AU - Cleland, John G F

AU - McMurray, John J V

AU - Aukrust, Pål

AU - Ueland, Thor

PY - 2015/8/19

Y1 - 2015/8/19

N2 - Background We have previously demonstrated an association between increased sFRP3 expression and adverse outcome in a population of HF irrespective of cause and left ventricular ejection fraction. In this study we evaluated the prognostic value of sFRP3 in older patients with chronic systolic HF of ischemic origin. Methods We evaluated sFRP3, by tertiles, as a risk factor for the primary endpoint (cardiovascular [CV] mortality, nonfatal myocardial infarction, nonfatal stroke), all-cause mortality, CV mortality, death from worsening HF (WHF), any coronary event, including sudden death, as well as hospitalizations for CV causes and WHF in 1444 patients from the CORONA population, randomly assigned to 10 mg rosuvastatin or placebo. Results Kaplan-Meier curves for the primary endpoint, as well as all-cause- and CV mortality revealed a markedly better survival for patients with sFRP3 levels in the middle tertile of compared to the 1st and 3rd tertile. In multivariable Cox-regression, after full adjustment including high-sensitive CRP and NT-proBNP, a lower event rate for the primary end point, all cause and CV mortality was observed for patients with tertile 2 sFRP3 levels (HR 0.57 [0.44-0.74], 0.55 [0.44-0.74] and 0.52 [0.39-0.69]; p

AB - Background We have previously demonstrated an association between increased sFRP3 expression and adverse outcome in a population of HF irrespective of cause and left ventricular ejection fraction. In this study we evaluated the prognostic value of sFRP3 in older patients with chronic systolic HF of ischemic origin. Methods We evaluated sFRP3, by tertiles, as a risk factor for the primary endpoint (cardiovascular [CV] mortality, nonfatal myocardial infarction, nonfatal stroke), all-cause mortality, CV mortality, death from worsening HF (WHF), any coronary event, including sudden death, as well as hospitalizations for CV causes and WHF in 1444 patients from the CORONA population, randomly assigned to 10 mg rosuvastatin or placebo. Results Kaplan-Meier curves for the primary endpoint, as well as all-cause- and CV mortality revealed a markedly better survival for patients with sFRP3 levels in the middle tertile of compared to the 1st and 3rd tertile. In multivariable Cox-regression, after full adjustment including high-sensitive CRP and NT-proBNP, a lower event rate for the primary end point, all cause and CV mortality was observed for patients with tertile 2 sFRP3 levels (HR 0.57 [0.44-0.74], 0.55 [0.44-0.74] and 0.52 [0.39-0.69]; p

UR - http://www.scopus.com/inward/record.url?scp=84942567332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942567332&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0133970

DO - 10.1371/journal.pone.0133970

M3 - Article

AN - SCOPUS:84942567332

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 8

M1 - e0133970

ER -